Purchase this article with an account.
M.P. Blair, R. Sjaarda, J. Thompson; Periocular Triamcinolone Acetate Injection for Treatment of Refractory Pseudophakic Cystoid Macular Edema . Invest. Ophthalmol. Vis. Sci. 2003;44(13):4943.
Download citation file:
© ARVO (1962-2015); The Authors (2016-present)
Purpose: To describe visual results of periocular injection of triamcinolone acetate to treat pseudophakic cystoid macular edema (CME) refractory to treatment with topical medications. Methods: A retrospective review was undertaken of the medical records of consecutive patients referred with pseudophakic CME. Patients were included if they were treated with one or more sub-Tenon’s injections of triamcinolone acetate, 40 mg in 1 ml. Patients were excluded if concomitant retinal vascular disorders were present including diabetes mellitus or retinal vein occlusion. Results: Thirty-three patients were identified. Follow-up prior to injection was variable, ranging from 0 to 26 weeks. Mean follow-up after injection was 11.6 weeks (range 4 to 30 weeks). Mean acuity prior to injection was 20/97. Four eyes had vision better than or equal to 20/40, while 18 had vision less than or equal to 20/100. At final follow-up mean visual acuity was 20/58. 14 eyes had visual acuity better than or equal to 20/40, while 8 had visual acuity less or equal to than 20/100. Intraocular pressure rose a mean of 0.58 mmHg (standard deviation 5.45, range -9 to 19 mmHg). Conclusions: Visual acuity and CME improve in some eyes refractory to medical therapy following a sub-Tenon’s injection of triamcinolone acetate. Further investigation in a prospective fashion is warranted.
This PDF is available to Subscribers Only